君实生物(01877)抗PD-1单抗鼻咽癌2期研究数据发表患者客观缓解率达61.9%

智通财经11-07

智通财经APP获悉，11月6日，君实生物(01877)宣布，针对顺铂不耐受的复发/转移性鼻咽癌(R/M NPC)患者的临床研究——特瑞普利单抗联合吉西他滨一线治疗顺铂不耐受的R/M NPC的2期研究最新数据在国际期刊《细胞报告医学》(Cell Reports Medicine)上发表。研究结果显示，患者客观缓解率(ORR)达61.9%，疾病控制率(DCR)为100%，中位无进展生存期(PFS)达...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2481299001?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-07 10:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481299001","market":"us","top_or_hot":-1,"title":"君实生物(01877)抗PD-1单抗鼻咽癌2期研究数据发表 患者客观缓解率达61.9%","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，11月6日，君实生物(01877)宣布，针对顺铂不耐受的复发/转移性鼻咽癌(R/M NPC)患者的临床研究——特瑞普利单抗联合吉西他滨一线治疗顺铂不耐受的R/M NPC的2期研究最新数据在国际期刊《细胞报告医学》(Cell Reports Medicine)上发表。研究结果显示，患者客观缓解率(ORR)达61.9%，疾病控制率(DCR)为100%，中位无进展生存期(PFS)达...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1207816.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>君实生物(01877)抗PD-1单抗鼻咽癌2期研究数据发表 患者客观缓解率达61.9%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n君实生物(01877)抗PD-1单抗鼻咽癌2期研究数据发表 患者客观缓解率达61.9%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-07 10:31 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1207816.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，11月6日，君实生物(01877)宣布，针对顺铂不耐受的复发/转移性鼻咽癌(R/M NPC)患者的临床研究——特瑞普利单抗联合吉西他滨一线治疗顺铂不耐受的R/M NPC的2期研究最新数据在国际期刊《细胞报告医学》(Cell Reports Medicine)上发表。研究结果显示，患者客观缓解率(ORR)达61.9%，疾病控制率(DCR)为100%，中位无进展生存期(PFS)达...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1207816.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4023","symbol_name":"应用软件","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1207816.html","article_id":"2481299001","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481299001","pubTimestamp":1730946703,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，11月6日，君实生物宣布，针对顺铂不耐受的复发/转移性鼻咽癌患者的临床研究——特瑞普利单抗联合吉西他滨一线治疗顺铂不耐受的R/M NPC的2期研究最新数据在国际期刊《细胞报告医学》上发表。以特瑞普利单抗为代表的抗PD-1单抗联合吉西他滨+顺铂方案已成为R/M NPC患者的一线标准治疗方案。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688180":"君实生物","BK4023":"应用软件","BK1583":"高瓴概念","PD":"PagerDuty, Inc.","BK0239":"医药制造","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","01877":"君实生物","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","BK1515":"抗疫概念","BK1161":"生物科技"},"translate_title":"Junshi Biotech (01877) anti-PD-1 monoclonal antibody phase 2 study data for nasopharyngeal carcinoma published, and the objective response rate of patients reached 61.9%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688180":1,"01877":1,"PD":1},"content_text":"智通财经APP获悉，11月6日，君实生物(01877)宣布，针对顺铂不耐受的复发/转移性鼻咽癌(R/M NPC)患者的临床研究——特瑞普利单抗联合吉西他滨一线治疗顺铂不耐受的R/M NPC的2期研究最新数据在国际期刊《细胞报告医学》(Cell Reports Medicine)上发表。研究结果显示，患者客观缓解率(ORR)达61.9%，疾病控制率(DCR)为100%，中位无进展生存期(PFS)达11.8个月，且毒性较标准含铂治疗显著降低，仅23.8%的患者发生≥3级不良事件(AE)。君实生物新闻稿表示，该治疗方案为R/M NPC顺铂不耐受患者带来了疗效和安全性的全面优化和升级。以特瑞普利单抗为代表的抗PD-1单抗联合吉西他滨+顺铂(GP)方案已成为R/M NPC患者的一线标准治疗方案。然而顺铂毒性较大，存在部分患者由于肾功能受损、体力状况较差、听力丧失或心力衰竭等原因无法耐受顺铂治疗。特瑞普利单抗已经相继在中国、美国、欧盟获批用于治疗R/M NPC。考虑到长期疗效和低毒性特征，本研究假设特瑞普利单抗联合毒性较小的化疗药物(吉西他滨)有望在不降低疗效的前提下提高安全性，最终达到去铂目的。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481299001"}

君实生物(01877)抗PD-1单抗鼻咽癌2期研究数据发表 患者客观缓解率达61.9%

精彩评论

君实生物(01877)抗PD-1单抗鼻咽癌2期研究数据发表患者客观缓解率达61.9%